Logo-jnp
J Nephropathol. Inpress.
doi: 10.34172/jnp.2023.17363
  Abstract View: 1123

Original Article

Evaluating the drug repurposing benefits of clopidogrel against adenine induced chronic renal failure in experimental animals

Rahul Hemani 1 ORCID logo, Priyal Patel 1, Sandip Patel 2, Alkeshkumar Patel 1* ORCID logo

1 Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), Changa, Anand, Gujarat, India
2 Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, Gujarat, India
*Corresponding Author: Corresponding author: Alkeshkumar Patel, Email: , Email: alkeshpatel.ph@charusat.ac.in

Abstract

Introduction: Chronic renal failure (CRF) is a life-threatening condition which can be defined as a progressive and irreversible loss of renal function associated with inflammation and oxidative stress having limited treatment options. The anti-platelet drug, clopidogrel showed nephroprotective action in 5/6 nephrectomy model, lithium induced nephrogenic diabetes insipidus and diabetes-induced renal fibrosis.

Objectives: In this study we evaluated the effect of clopidogrel on various serum, urine parameters linked with CRF, vascular calcification, electrolyte abnormalities, inflammatory markers and renal histology.

Materials and Methods: Seven groups of male Wistar rats were treated with saline normal control), adenine (50 mg/kg, disease control), clopidogrel (15, 30, 60 mg/kg) concomitantly with adenine (preventive regimen), clopidogrel 60 mg/kg from day 15th curative regimen) and acetylcysteine (50 mg/kg) in combination with taurine as standard drug (50 mg/kg) from day 15th in a 4-week model. Following the completion of the treatments, urine, blood, and kidneys were collected from all rats, and then various biochemical, oxidative, and histological parameters were estimated.

Results: Adenine administration decreased body weight and kidney function due to injury as indicated by increased markers like serum urea, uric acid, creatinine and potassium in all animals except normal control group. There was a significant difference between disease and test drug groups especially for 60 mg/kg of preventive and curative regimen for all the estimated parameters. Adenine administration caused histopathological alterations, significant reduction in antioxidant indices and initiated a fibrotic response in kidney by increasing the profibrotic protein like transforming growth factor-beta (TGF-β1).

Conclusion: The results suggest that clopidogrel treatment improves majority of the parameters in a dose-dependent manner and the renoprotective effect might be associated with its antioxidant and anti- fibrosis activity.


Implication for health policy/practice/research/medical education:

Chronic kidney disease is a progressive illness, becoming a significant concern of community and among the world’s leading cause of mortality. Adenine elevates creatinine and urea level in the serum, causes proteinuria and fibrosis in animals. Furthermore, the model resulted in a substantial reduction in free amino acid and calcium concentrations, hyper-lipidaemia, and vascular calcification, all of which are characteristics of human CKD. Clopidogrel, an anti-platelet drug acts by inhibiting ADP- induced P2Y12 receptor activation and thus inhibits platelet activation and aggregation. Clopidogrel repurposed based on its lowering plasma levels of urea and creatinine, reduced blood glucose, collagen. Clopidogrel preventing a decrease in cellular cAMP levels, may have a significant ameliorative effect on adenine-induced CRF.

Please cite this paper as: Hemani R, Patel P, Patel S, Patel A. Evaluating the drug repurposing benefits of clopidogrel against adenine induced chronic renal failure in experimental animals. J Nephropathol. 2023;x(x):e17363. DOI: 10.34172/jnp.2023.17363.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 1124

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.

Submitted: 31 Mar 2022
Accepted: 06 Mar 2023
ePublished: 10 Apr 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)